MOA
MCID: OLG006
MIFTS: 35

Oligoastrocytoma (MOA) malady

Categories: Rare diseases, Neuronal diseases

Aliases & Classifications for Oligoastrocytoma

Aliases & Descriptions for Oligoastrocytoma:

Name: Oligoastrocytoma 50 56 29
Mixed Oligoastrocytoma 56 69
Mixed Oligodendroglioma-Astrocytoma 69
Oligoastrocytoma Mixed 52
Moa 56

Classifications:

Orphanet: 56  
Rare neurological diseases


External Ids:

Orphanet 56 ORPHA251656
UMLS via Orphanet 70 C0280793
ICD10 via Orphanet 34 C71.9

Summaries for Oligoastrocytoma

NIH Rare Diseases : 50 oligoastrocytoma is a brain tumor that forms when two types of cells in the brain, called oligodendrocytes and astrocytes, rapidly increase in number to form a mass.  these brain cells are known as glial cells, which normally protect and support nerve cells in the brain.  because an oligoastrocytoma is made up of a combination of two cell types, it is known as a mixed glioma.  oligoastrocytomas usually occur in a part of the brain called the cerebrum and are diagnosed in adults between the ages of 30 and 50.  the exact cause of this condition is unknown. last updated: 10/5/2012

MalaCards based summary : Oligoastrocytoma, also known as mixed oligoastrocytoma, is related to anaplastic oligoastrocytoma and oligodendroglioma, and has symptoms including headache and seizures. An important gene associated with Oligoastrocytoma is IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2, Mitochondrial). The drugs Dacarbazine and Temozolomide have been mentioned in the context of this disorder. Affiliated tissues include brain, bone and bone marrow.

Wikipedia : 71 Oligoastrocytomas are a subset of brain tumors that present with an appearance of mixed glial cell... more...

Related Diseases for Oligoastrocytoma

Diseases related to Oligoastrocytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 44)
id Related Disease Score Top Affiliating Genes
1 anaplastic oligoastrocytoma 12.3
2 oligodendroglioma 10.3
3 anaplastic oligodendroglioma 10.1
4 astrocytoma 10.1
5 brain stem astrocytic neoplasm 10.0 GFAP MGMT
6 cutaneous adenocystic carcinoma 10.0 GFAP MGMT
7 fallopian tube benign neoplasm 10.0 GFAP MGMT
8 early myoclonic encephalopathy 10.0 GFAP MGMT
9 epimetaphyseal dysplasia cataract 10.0 GFAP MGMT
10 marginal zone b-cell lymphoma 10.0 GFAP MGMT
11 juvenile astrocytoma 10.0 GFAP MGMT
12 glomeruloid hemangioma 10.0 GFAP MGMT
13 angioma hereditary neurocutaneous 9.9 IDH2 MGMT
14 nodular goiter 9.9 GFAP MGMT
15 bile duct clear cell adenocarcinoma 9.9 GFAP IDH2
16 malignant pleural solitary fibrous tumor 9.9 GFAP MGMT
17 basal cell nevus syndrome 9.9 GFAP MGMT
18 bronchial mucus gland adenoma 9.9 GFAP IDH2
19 adult astrocytic tumour 9.9 GFAP MGMT
20 glioma 9.9
21 grade iii astrocytoma 9.8 GFAP MGMT
22 leukemia 9.8
23 mixed glioma 9.8
24 ophn1 syndrome 9.7 GFAP IDH2 MGMT
25 amyloid tumor 9.7 GFAP IDH2 MGMT
26 interstitial lung disease 9.7 GFAP IDH2 MGMT
27 adult oligodendroglioma 9.7 GFAP IDH2 MGMT
28 medulloblastoma 9.6
29 focal dystonia 9.6
30 cerebrospinal fluid leak 9.6
31 myelomeningocele 9.6
32 glioblastoma 9.6
33 cysticercosis 9.6
34 dermatomyositis 9.6
35 opsoclonus-myoclonus syndrome 9.6
36 lymphoblastic leukemia 9.6
37 transverse myelitis 9.6
38 epilepsy 9.6
39 myoclonus 9.6
40 myelitis 9.6
41 cerebritis 9.6
42 dystonia 9.6
43 paraplegia 9.6
44 myeloid leukemia 9.6

Graphical network of the top 20 diseases related to Oligoastrocytoma:



Diseases related to Oligoastrocytoma

Symptoms & Phenotypes for Oligoastrocytoma

UMLS symptoms related to Oligoastrocytoma:


headache, seizures

Drugs & Therapeutics for Oligoastrocytoma

Drugs for Oligoastrocytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 167)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dacarbazine Approved, Investigational Phase 3,Phase 2,Phase 1 4342-03-4 5351166
2
Temozolomide Approved, Investigational Phase 3,Phase 2,Phase 1 85622-93-1 5394
3
Carmustine Approved Phase 3 154-93-8 2578
4
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
5
Procarbazine Approved Phase 3 671-16-9 4915
6
Lomustine Approved Phase 3 13010-47-4 3950
7
Benzocaine Approved Phase 3 1994-09-7, 94-09-7 2337
8
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
9
Cyproheptadine Approved Phase 3 129-03-3 2913
10 tannic acid Approved, Nutraceutical Phase 3
11 Alkylating Agents Phase 3,Phase 2,Phase 1
12 Dermatologic Agents Phase 3,Phase 1,Phase 2
13 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
14 interferons Phase 3,Phase 1,Early Phase 1
15 Gastrointestinal Agents Phase 3,Phase 1,Early Phase 1
16 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Early Phase 1
17 Antiviral Agents Phase 3,Phase 1,Early Phase 1
18 Interferon-alpha Phase 3
19
Histamine Phosphate Phase 3 51-74-1 65513
20
Serotonin Phase 3 50-67-9 5202
21 Serotonin Agents Phase 3
22 Serotonin Antagonists Phase 3
23 Neurotransmitter Agents Phase 3
24 Histamine Antagonists Phase 3
25 Histamine H1 Antagonists Phase 3
26 Anti-Allergic Agents Phase 3
27 Antipruritics Phase 3
28
Trioxsalen Approved Phase 2,Phase 1 3902-71-4 5585
29
Topotecan Approved, Investigational Phase 2 119413-54-6, 123948-87-8 60700
30
Irinotecan Approved, Investigational Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
31
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 498142 38904
32
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 50-18-0, 6055-19-2 2907
33
Hydroxyurea Approved Phase 2 127-07-1 3657
34
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
35
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177
36
Thiotepa Approved Phase 2 52-24-4 5453
37
Lenograstim Approved Phase 2 135968-09-1
38
Nintedanib Approved Phase 2 656247-17-5 56843413
39
Bevacizumab Approved, Investigational Phase 2,Phase 1 216974-75-3
40
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
41
Mannitol Approved, Investigational Phase 1, Phase 2 69-65-8 453 6251
42
Etoposide Approved Phase 1, Phase 2 33419-42-0 36462
43
Melphalan Approved Phase 1, Phase 2 148-82-3 4053 460612
44
Mechlorethamine Approved Phase 1, Phase 2 51-75-2 4033
45
Cetuximab Approved Phase 2,Phase 1 205923-56-4 56842117 2333
46 Sodium thiosulfate Approved Phase 1, Phase 2
47
Palbociclib Approved Phase 2,Phase 1 571190-30-2 11431660 5005498 5330286
48
Dexamethasone Approved, Investigational, Vet_approved Phase 2,Phase 1 50-02-2 5743
49
Acetaminophen Approved Phase 2 103-90-2 1983
50
Diphenhydramine Approved Phase 2 58-73-1, 147-24-0 3100

Interventional clinical trials:

(show top 50) (show all 98)
id Name Status NCT ID Phase
1 Safety and Efficacy Study of Intracranially Implanted Carmustine to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3
2 Randomized Phase III Study of Sequential Radiochemotherapy of Anaplastic Glioma With PCV or Temozolomide Completed NCT00717210 Phase 3
3 A Study on β-elemene as Maintain Treatment for Complete Remission Patients of Newly Diagnosed Malignant Gliomas Following Standard Treatment Recruiting NCT02629757 Phase 3
4 A Phase III Trial on Adjuvant Temozolomide With or Without Interferon-alpha in Newly Diagnosed High-grade Gliomas Recruiting NCT01765088 Phase 3
5 Radiation Therapy Combined With Chemotherapy in Treating Patients With Anaplastic Astrocytoma or Mixed Gliomas Active, not recruiting NCT00004259 Phase 3
6 Treatment Strategy for Low-grade Gliomas Terminated NCT00897377 Phase 3
7 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3
8 Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2
9 A Prospective Cohort to Study the Effect of Temozolomide on IDH Mutational Low Grade Gliomas Unknown status NCT02209428 Phase 2
10 131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma Unknown status NCT00114309 Phase 2
11 Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendroglioma and Mixed Oligoastrocytoma Completed NCT00362570 Phase 2
12 Temozolomide in Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: Single-arm, Phase II Trial Completed NCT01847235 Phase 2
13 Topotecan in Treating Patients With Recurrent Brain Tumors Completed NCT00003372 Phase 2
14 Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma Completed NCT00008008 Phase 2
15 Phase II Trial of RAD001 in Patients With Recurrent Low Grade Glioma Completed NCT00823459 Phase 2
16 Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors Completed NCT00667394 Phase 2
17 Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma Completed NCT00041587 Phase 1, Phase 2
18 Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma Completed NCT00024570 Phase 1, Phase 2
19 Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG) Completed NCT00615927 Phase 2
20 Bevacizumab for Recurrent Malignant Glioma Completed NCT00271609 Phase 2
21 BIBF 1120 for Recurrent High-Grade Gliomas Completed NCT01380782 Phase 2
22 A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas Completed NCT00995007 Phase 2
23 Prolonged Daily Temozolomide for Low-Grade Glioma Completed NCT00165360 Phase 2
24 Cilengitide in Treating Younger Patients With Recurrent or Progressive High-Grade Glioma That Has Not Responded to Standard Therapy Completed NCT00679354 Phase 2
25 Phase (Ph) II Bevacizumab + Erlotinib for Patients (Pts) With Recurrent Malignant Glioma (MG) Completed NCT00671970 Phase 2
26 Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved Recruiting NCT02530320 Phase 2
27 Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors Recruiting NCT00303849 Phase 1, Phase 2
28 Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA Recruiting NCT02800486 Phase 2
29 Everolimus With and Without Temozolomide in Adult Low Grade Glioma Recruiting NCT02023905 Phase 2
30 Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients With IDH Mutant Grade II or III Glioma Recruiting NCT03180502 Phase 2
31 Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas Recruiting NCT01966809 Phase 2
32 Intraarterial Infusion Of Erbitux and Bevacizumab For Relapsed/Refractory Intracranial Glioma In Patients Under 22 Recruiting NCT01884740 Phase 1, Phase 2
33 Temozolomide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Anaplastic Oligodendrogliomas or Mixed Anaplastic Oligoastrocytomas Active, not recruiting NCT00033280 Phase 2
34 Temozolomide in Treating Patients With Newly Diagnosed Anaplastic Oligodendroglioma or Mixed Oligoastrocytoma Active, not recruiting NCT00400816 Phase 2
35 Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor Active, not recruiting NCT00049127 Phase 1, Phase 2
36 Vaccine for Patients With Newly Diagnosed or Recurrent Low-Grade Glioma Active, not recruiting NCT01635283 Phase 2
37 Vorinostat and Radiation Therapy Followed by Maintenance Therapy With Vorinostat in Treating Younger Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma Active, not recruiting NCT01189266 Phase 1, Phase 2
38 Crizotinib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Active, not recruiting NCT00939770 Phase 1, Phase 2
39 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Active, not recruiting NCT00445965 Phase 2
40 A Phase 2 Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Patients With Recurrent Gliomas Active, not recruiting NCT01986348 Phase 2
41 Phase II Pediatric Study With Dabrafenib in HGG Patients Not yet recruiting NCT02684058 Phase 2
42 Trial of IDH305 in IDH1 Mutant Grade II or III Glioma Not yet recruiting NCT02977689 Phase 2
43 A Phase II Study of Temozolomide and O6-Benzylguanine (O6-BG) in Patients With Temozolomide-Resistant Anaplastic Glioma Terminated NCT00389090 Phase 2
44 Phase 2 Trial Using Talampanel in Patients With Recurrent High Grade Gliomas Terminated NCT00062504 Phase 2
45 Study of LBH589 (Panobinostat) to Treat Malignant Brain Tumors Terminated NCT00848523 Phase 2
46 Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM) Terminated NCT01110876 Phase 1, Phase 2
47 Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme (Phase II) Withdrawn NCT02369367 Phase 2
48 Phase I/II Cabazitaxel for Recurrent Malignant Glioma Withdrawn NCT01740570 Phase 1, Phase 2
49 Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors Unknown status NCT00002647 Phase 1
50 Sorafenib in Newly Diagnosed High Grade Glioma Completed NCT00884416 Phase 1

Search NIH Clinical Center for Oligoastrocytoma

Genetic Tests for Oligoastrocytoma

Genetic tests related to Oligoastrocytoma:

id Genetic test Affiliating Genes
1 Oligoastrocytoma 29

Anatomical Context for Oligoastrocytoma

MalaCards organs/tissues related to Oligoastrocytoma:

39
Brain, Bone, Bone Marrow, Spinal Cord, Myeloid

Publications for Oligoastrocytoma

Articles related to Oligoastrocytoma:

(show top 50) (show all 82)
id Title Authors Year
1
Unique case of oligoastrocytoma with recurrence and grade progression: Exhibiting differential expression of high mobility group-A1 and human telomerase reverse transcriptase. ( 27672647 )
2016
2
A rare case of oligoastrocytoma with atypical symptoms initially diagnosed as multiple sclerosis: A case report. ( 26893863 )
2016
3
Primary Spinal Oligoastrocytoma. ( 27092919 )
2016
4
Neurosurgery concepts: Key perspectives on intrathecal fluorescein for detecting intraoperative cerebrospinal fluid leak during endoscopic endonasal surgery, spinal intraarterial chemotherapy, oligoastrocytoma classification by in situ molecular genetics, and prenatal myelomeningocele closure and the need for cerebrospinal fluid shunt placement. ( 27857862 )
2016
5
Focal seizure induced by preoperative navigated transcranial magnetic stimulation in a patient with anaplastic oligoastrocytoma. ( 28017645 )
2016
6
A case of medulloblastoma in adult patient affected by anaplastic oligoastrocytoma. ( 27329275 )
2016
7
Overview of Transgenic Glioblastoma and Oligoastrocytoma CNS Models and Their Utility in Drug Discovery. ( 26995546 )
2016
8
Primary spinal cord anaplastic oligoastrocytoma presenting with paraplegia. ( 26851716 )
2016
9
Anaplastic oligoastrocytoma: is molecular stratification based on 1p/19q status alone appropriate? ( 25555564 )
2015
10
Does morphological assessment have a role in classifying oligoastrocytoma as "oligodendroglial" vs. "astrocytic"? ( 26466141 )
2015
11
Solitary "aggressive" leptomeningeal anaplastic oligoastrocytoma. ( 26318905 )
2015
12
Primary spinal oligoastrocytoma mimicking longitudinally extensive transverse myelitis. ( 26590667 )
2015
13
Opsoclonus-myoclonus syndrome in a patient with an anaplastic oligoastrocytoma. ( 25864100 )
2015
14
Treatment updates regarding anaplastic oligodendroglioma and anaplastic oligoastrocytoma. ( 25523732 )
2014
15
Clinical discussion of the management of anaplastic oligodendroglioma/oligoastrocytoma (both codeleted and nondeleted). ( 24812135 )
2014
16
Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. ( 25143301 )
2014
17
Mixed Glioma (Oligoastrocytoma) in the Brain ofA an African Hedgehog (Atelerix albiventris). ( 25172052 )
2014
18
High expression of the stem cell marker nestin is an adverse prognostic factor in WHO grade II-III astrocytomas and oligoastrocytomas. ( 24519516 )
2014
19
Pattern of care of anaplastic oligodendroglioma and oligoastrocytoma in a Korean population: the Korean radiation oncology group study 13-12. ( 25391968 )
2014
20
Successful use of metronomic vinblastine and fluorothymidine pet imaging for the management of intramedullary spinal cord anaplastic oligoastrocytoma in a child. ( 25489269 )
2014
21
Health-related quality of life and cognitive functioning in long-term anaplastic oligodendroglioma and oligoastrocytoma survivors. ( 24162809 )
2014
22
Farewell to oligoastrocytoma: response to letters. ( 25381649 )
2014
23
Experiential auditory hallucinations due to chronic epileptic discharges after radiotherapy for oligoastrocytoma. ( 23774105 )
2013
24
Analysis of CIC-associated CpG-island methylation in oligoastrocytoma. ( 23521081 )
2013
25
Infratentorial low-grade oligoastrocytoma with aggressive clinical behavior in an adult: a case report with genetic characterization. ( 22752622 )
2013
26
1p/19q codeletion and IDH1/2 mutation identified a subtype of anaplastic oligoastrocytomas with prognosis as favorable as anaplastic oligodendrogliomas. ( 23486687 )
2013
27
New clinical, pathological and molecular prognostic models and calculators in patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. ( 23896377 )
2013
28
CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas. ( 22588899 )
2012
29
Cerebellar low-grade oligoastrocytoma presenting with subarachnoid haemorrhage. ( 22665014 )
2012
30
Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology. ( 21069360 )
2011
31
Up-front temozolomide in elderly patients with anaplastic oligodendroglioma and oligoastrocytoma. ( 20556480 )
2011
32
Intrathecal liposomal cytarabine in combination with temozolomide in low-grade oligoastrocytoma with leptomeningeal dissemination. ( 19876600 )
2010
33
Preoperative chemotherapy for infiltrative low-grade oligoastrocytoma: a useful strategy to maximize surgical resection -case report-. ( 20505301 )
2010
34
Anaplastic oligoastrocytoma in Turcot syndrome. ( 19495563 )
2009
35
Oligoastrocytoma of the brain in a hooded crane (Grus monacha). ( 19261644 )
2009
36
Novel genomic alterations and mechanisms associated with tumor progression in oligodendroglioma and mixed oligoastrocytoma. ( 19225409 )
2009
37
Multi-focal cerebral oligoastrocytoma in a puppy. ( 19689673 )
2009
38
A multicenter cohort study of dose-dense temozolomide (21 of 28 days) for the treatment of recurrent anaplastic astrocytoma or oligoastrocytoma. ( 18317968 )
2008
39
Autoimmunity manifesting as dermatomyositis associated with oligoastrocytoma and dendritic cell immunotherapy. ( 18443006 )
2008
40
Genetically distinct astrocytic and oligodendroglial components in oligoastrocytomas. ( 17031656 )
2007
41
Prognosis in patients with anaplastic oligoastrocytoma is associated with histologic grade. ( 17431544 )
2007
42
Intradural extramedullary spinal spread of oligoastrocytoma. ( 17582770 )
2007
43
Qualitative and quantitative analysis of cytologic assessment of astrocytoma, oligodendroglioma and oligoastrocytoma. ( 18077983 )
2007
44
Oligoastrocytoma presenting with intractable epilepsy. ( 17884756 )
2007
45
Anaplastic oligoastrocytoma: previous treatment as a possible cause in a child with acute lymphoblastic leukemia. ( 17043901 )
2007
46
Malignant transformation of oligoastrocytoma: a case report. ( 18095133 )
2007
47
Anaplastic oligodendroglioma and oligoastrocytoma. ( 17964027 )
2007
48
Isolation and characterization of stem cell-like precursor cells from primary human anaplastic oligoastrocytoma. ( 17660801 )
2007
49
Interstitial 125I radiosurgery of supratentorial de novo WHO Grade 2 astrocytoma and oligoastrocytoma in adults: long-term results and prognostic factors. ( 16470609 )
2006
50
Positive reaction for cysticercosis and multicentric anaplastic oligoastrocytoma. ( 15778869 )
2006

Variations for Oligoastrocytoma

Expression for Oligoastrocytoma

Search GEO for disease gene expression data for Oligoastrocytoma.

Pathways for Oligoastrocytoma

GO Terms for Oligoastrocytoma

Sources for Oligoastrocytoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....